There are 3 listed Diagnostic Services stocks in India: Dr Lal Pathlabs (₹33,690 crore), 3B Blackbio DX (₹1,124 crore) and Chandan Healthcare (₹586 crore), at prices of 20 November 2026. 0 of the 3 companies we track are beating the Nifty 500 on share price over recent months.
Diagnostic Services: Dr Lal Pathlabs Ltd owns the largest revenue base; 3B Blackbio DX Ltd has the fastest current growth.
The main question: the biggest companies are not always the ones changing the most.
Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.
How big is the Diagnostic Services sector?
There are 3 listed Diagnostic Services companies on this page, worth ₹35,400 cr together at prices of 20 November 2026. Dr Lal Pathlabs alone is ₹33,700 cr, about 95% of the total.
Market values at prices of 20 November 2026.
What did Diagnostic Services managements say about July to September 2026?
7 of 10 Diagnostic Services companies held a results call for July to September 2026. Suraksha Diagnostic guided: FY27 revenue growth 15%-18% commitment with best-possible effort for higher outcome.
Suraksha Diagnostic call 13 November 2026
“While this remains a relatively small vertical today, we strongly believe that it has the potential to become a very meaningful pillar of our business as we continue to scale this platform.”Dr. Somnath Chatterjee
Guided: FY27 revenue growth 15%-18% commitment with best-possible effort for higher outcome.
Dr Lal Pathlabs call 4 November 2026
“This is the highest quarterly growth in the last 5 years and has been driven by 9% growth in patient volumes.”Shankha Banerjee
Guided: FY27 revenue growth high-teens on broad volume after first-half beat.
Metropolis Healthcare call 4 November 2026
Ameera Shah
Guided: H2 revenue growth similar to H1 volume-mix trend through rest of year.
Vijaya Diagnostic Centre call 4 November 2026
“I am particularly pleased to share that our Hyderabad business continued its strong performance, growing by over 20% year-on-year, while Pune also delivered encouraging growth of approximately 15.5% year-on-year.”Narasimha Raju
Guided: FY27 revenue growth at least 20% achievable on broad-based strength.
Krsnaa Diagnostics call 3 November 2026
“For the first time, Krsnaa Diagnostics has crossed Rs.500 crores in revenue in the last six months, achieving Rs.507 crores in H1 FY27. Despite the natural completion of certain contracts, Krsnaa has delivered an impressive 27% year-on-year growth.”Yash Mutha
Guided: Cash-based revenues 40-45% of mix aggregating around ₹400 crore for FY27 by year-end.
Vimta Labs call 30 October 2026
“A key milestone during Q2 was the commencement of revenue generation from our biologics services.”Harita Vasireddi
Guided: FY28 revenue around ₹700 crore implying around 20-25% yearly growth with operating profit 35-36%.
Thyrocare Technologies call 29 October 2026
“I would say that a long-term guidance of about 31% to 31.5%, where we are funding all these investments for growth, is what I would anchor on, and not above that.”Rahul Guha, MD and CEO
Guided: FY27 revenue growth seen in early-20s percent.
From the results calls for July to September 2026.
Is money moving into Diagnostic Services stocks? Who is adding capacity?
Big funds, foreign and Indian, raised their stake by 0.3 points over the last two quarters. Founders and promoters cut theirs by 0.9 points.
- Spending on new plants and equipment was ₹495 crore in the last 12 months, 29% more than a year before.
- Projects still being built grew 171% in a year.
Big funds = foreign and Indian institutions, change in their share of ownership across 3 Diagnostic Services companies, in percentage points.
Ownership and spending as of 10 October 2026.
Which are the biggest Diagnostic Services stocks in India?
The largest Diagnostic Services stocks in India by market value are Dr Lal Pathlabs (₹33,690 crore), 3B Blackbio DX (₹1,124 crore) and Chandan Healthcare (₹586 crore), at prices of 20 Nov 2026.
- Dr Lal Pathlabs: ₹2,006.55 | market value ₹33,690 crore | P/E 57.2
- 3B Blackbio DX: ₹1,305.05 | market value ₹1,124 crore | P/E 20.5
- Chandan Healthcare: ₹240 | market value ₹586 crore | P/E 24.1
Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 20 Nov 2026; the score list below uses the weekly figures.
Is there a Nifty Diagnostic Services index, and what is in it?
All 3 listed Indian Diagnostic Services companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Diagnostic Services index; the exchange publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. Every figure is equal-weighted across those companies and carries its own as-of date.
- Dr Lal Pathlabs Ltd₹33,700 cr
- 3B Blackbio DX Ltd₹1,120 cr
- Chandan Healthcare Ltd₹586 cr
How many Diagnostic Services companies are listed in India?
3 Diagnostic Services companies in the Diagnostic Services industry group have a page on Sector Alpha, and all 3 are listed below, largest first. The largest is Dr Lal Pathlabs (₹33,690 crore) and the smallest with a market value is Chandan Healthcare.
| Company | Market value |
|---|---|
| 1. Dr Lal Pathlabs Ltd LALPATHLAB | ₹33,690 crore |
| 2. 3B Blackbio DX Ltd 3BBLACKBIO | ₹1,124 crore |
| 3. Chandan Healthcare Ltd CHANDAN | ₹586 crore |
How has Diagnostic Services moved against NIFTY 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 16% ahead of NIFTY 500. Earnings across its companies grew 17% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 13 weeks running.
Price and the fundamentals both up. 0 of 3 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).
Ahead of NIFTY 500 on the three-month view for 13 weeks running; 1 of the 3 companies in the industry index above their 200-day average (1 fewer than four weeks earlier); 0 of those 3 pass the momentum test (2 fewer than four weeks earlier); earnings direction not measurable.
Participation is shrinking, 2 → 0 of 3 over four weeks, after being ahead of NIFTY 500. Earnings not called, only 2 of 3 members have four comparable quarters on file, and three is the floor for a reading.
1Y
Diagnostic Services against NIFTY 500
Both lines start at 200 in the first week shown
- Diagnostic Services 206
- NIFTY 500 200
| Week ending | Diagnostic Services | NIFTY 500 |
|---|---|---|
| 21 Nov 2025 | 200 | 200 |
| 28 Nov 2025 | 199 | 201 |
| 5 Dec 2025 | 195 | 200 |
| 12 Dec 2025 | 193 | 199 |
| 19 Dec 2025 | 188 | 199 |
| 26 Dec 2025 | 198 | 200 |
| 2 Jan 2026 | 200 | 203 |
| 9 Jan 2026 | 196 | 197 |
| 16 Jan 2026 | 199 | 197 |
| 23 Jan 2026 | 196 | 191 |
| 30 Jan 2026 | 197 | 194 |
| 6 Feb 2026 | 200 | 197 |
| 13 Feb 2026 | 199 | 196 |
| 20 Feb 2026 | 196 | 197 |
| 27 Feb 2026 | 184 | 195 |
| 6 Mar 2026 | 178 | 189 |
| 13 Mar 2026 | 173 | 180 |
| 20 Mar 2026 | 175 | 179 |
| 27 Mar 2026 | 166 | 177 |
| 3 Apr 2026 | 174 | 176 |
| 10 Apr 2026 | 178 | 188 |
| 17 Apr 2026 | 183 | 192 |
| 24 Apr 2026 | 181 | 190 |
| 1 May 2026 | 175 | 191 |
| 8 May 2026 | 192 | 194 |
| 15 May 2026 | 192 | 189 |
| 22 May 2026 | 182 | 190 |
| 29 May 2026 | 185 | 190 |
| 5 Jun 2026 | 175 | 189 |
| 12 Jun 2026 | 181 | 190 |
| 19 Jun 2026 | 176 | 195 |
| 26 Jun 2026 | 186 | 194 |
| 3 Jul 2026 | 187 | 196 |
| 10 Jul 2026 | 186 | 196 |
| 17 Jul 2026 | 187 | 196 |
| 24 Jul 2026 | 191 | 193 |
| 31 Jul 2026 | 197 | 197 |
| 7 Aug 2026 | 194 | 199 |
| 14 Aug 2026 | 196 | 198 |
| 21 Aug 2026 | 193 | 198 |
| 28 Aug 2026 | 203 | 198 |
| 4 Sep 2026 | 200 | 195 |
| 11 Sep 2026 | 196 | 192 |
| 18 Sep 2026 | 191 | 192 |
| 25 Sep 2026 | 212 | 190 |
| 2 Oct 2026 | 219 | 184 |
| 9 Oct 2026 | 216 | 184 |
| 16 Oct 2026 | 208 | 187 |
| 23 Oct 2026 | 196 | 180 |
| 30 Oct 2026 | 202 | 184 |
| 6 Nov 2026 | 204 | 197 |
| 13 Nov 2026 | 206 | 200 |
3Y
Diagnostic Services against NIFTY 500
Both lines start at 200 in the first week shown, every 2nd week shown
- Diagnostic Services 415
- NIFTY 500 269
| Week ending | Diagnostic Services | NIFTY 500 |
|---|---|---|
| 24 Nov 2023 | 200 | 200 |
| 1 Dec 2023 | 200 | 205 |
| 15 Dec 2023 | 198 | 217 |
| 29 Dec 2023 | 206 | 220 |
| 12 Jan 2024 | 201 | 224 |
| 26 Jan 2024 | 204 | 220 |
| 9 Feb 2024 | 204 | 226 |
| 23 Feb 2024 | 215 | 230 |
| 8 Mar 2024 | 193 | 232 |
| 22 Mar 2024 | 183 | 227 |
| 5 Apr 2024 | 189 | 235 |
| 19 Apr 2024 | 188 | 231 |
| 3 May 2024 | 190 | 238 |
| 17 May 2024 | 207 | 239 |
| 31 May 2024 | 223 | 239 |
| 14 Jun 2024 | 255 | 252 |
| 28 Jun 2024 | 259 | 256 |
| 12 Jul 2024 | 265 | 262 |
| 26 Jul 2024 | 265 | 264 |
| 9 Aug 2024 | 287 | 260 |
| 23 Aug 2024 | 326 | 265 |
| 6 Sep 2024 | 327 | 266 |
| 20 Sep 2024 | 311 | 274 |
| 4 Oct 2024 | 318 | 267 |
| 18 Oct 2024 | 316 | 266 |
| 1 Nov 2024 | 315 | 259 |
| 15 Nov 2024 | 335 | 249 |
| 29 Nov 2024 | 334 | 257 |
| 13 Dec 2024 | 377 | 265 |
| 27 Dec 2024 | 365 | 254 |
| 10 Jan 2025 | 361 | 247 |
| 24 Jan 2025 | 345 | 242 |
| 7 Feb 2025 | 358 | 245 |
| 21 Feb 2025 | 333 | 235 |
| 7 Mar 2025 | 330 | 232 |
| 21 Mar 2025 | 335 | 241 |
| 4 Apr 2025 | 344 | 236 |
| 18 Apr 2025 | 354 | 246 |
| 2 May 2025 | 341 | 249 |
| 16 May 2025 | 336 | 259 |
| 30 May 2025 | 339 | 258 |
| 13 Jun 2025 | 351 | 260 |
| 27 Jun 2025 | 327 | 268 |
| 11 Jul 2025 | 346 | 264 |
| 25 Jul 2025 | 371 | 261 |
| 8 Aug 2025 | 378 | 254 |
| 22 Aug 2025 | 379 | 261 |
| 5 Sep 2025 | 373 | 259 |
| 19 Sep 2025 | 371 | 266 |
| 3 Oct 2025 | 367 | 261 |
| 17 Oct 2025 | 395 | 268 |
| 31 Oct 2025 | 410 | 269 |
| 14 Nov 2025 | 407 | 270 |
| 28 Nov 2025 | 401 | 271 |
| 12 Dec 2025 | 388 | 269 |
| 26 Dec 2025 | 400 | 270 |
| 9 Jan 2026 | 395 | 266 |
| 23 Jan 2026 | 394 | 257 |
| 6 Feb 2026 | 403 | 266 |
| 20 Feb 2026 | 394 | 265 |
| 6 Mar 2026 | 359 | 255 |
| 20 Mar 2026 | 354 | 242 |
| 3 Apr 2026 | 350 | 237 |
| 17 Apr 2026 | 369 | 259 |
| 1 May 2026 | 352 | 257 |
| 15 May 2026 | 387 | 255 |
| 29 May 2026 | 374 | 257 |
| 12 Jun 2026 | 366 | 256 |
| 26 Jun 2026 | 374 | 262 |
| 10 Jul 2026 | 376 | 265 |
| 24 Jul 2026 | 385 | 260 |
| 7 Aug 2026 | 391 | 269 |
| 21 Aug 2026 | 388 | 267 |
| 4 Sep 2026 | 403 | 264 |
| 18 Sep 2026 | 386 | 259 |
| 2 Oct 2026 | 442 | 248 |
| 16 Oct 2026 | 420 | 252 |
| 30 Oct 2026 | 407 | 248 |
| 13 Nov 2026 | 415 | 269 |
5Y
Diagnostic Services against NIFTY 500
Both lines start at 200 in the first week shown, every 4th week shown
- Diagnostic Services 488
- NIFTY 500 323
| Week ending | Diagnostic Services | NIFTY 500 |
|---|---|---|
| 26 Nov 2021 | 200 | 200 |
| 17 Dec 2021 | 190 | 200 |
| 14 Jan 2022 | 205 | 214 |
| 11 Feb 2022 | 166 | 203 |
| 11 Mar 2022 | 165 | 194 |
| 8 Apr 2022 | 164 | 209 |
| 6 May 2022 | 147 | 192 |
| 3 Jun 2022 | 138 | 191 |
| 1 Jul 2022 | 134 | 182 |
| 29 Jul 2022 | 138 | 199 |
| 26 Aug 2022 | 162 | 206 |
| 23 Sep 2022 | 153 | 205 |
| 21 Oct 2022 | 150 | 205 |
| 18 Nov 2022 | 164 | 211 |
| 16 Dec 2022 | 163 | 213 |
| 13 Jan 2023 | 162 | 209 |
| 10 Feb 2023 | 145 | 204 |
| 10 Mar 2023 | 142 | 200 |
| 7 Apr 2023 | 147 | 201 |
| 5 May 2023 | 151 | 208 |
| 2 Jun 2023 | 149 | 215 |
| 30 Jun 2023 | 161 | 223 |
| 28 Jul 2023 | 175 | 230 |
| 25 Aug 2023 | 190 | 229 |
| 22 Sep 2023 | 224 | 235 |
| 20 Oct 2023 | 232 | 234 |
| 17 Nov 2023 | 237 | 239 |
| 15 Dec 2023 | 233 | 260 |
| 12 Jan 2024 | 236 | 269 |
| 9 Feb 2024 | 240 | 271 |
| 8 Mar 2024 | 227 | 278 |
| 5 Apr 2024 | 222 | 282 |
| 3 May 2024 | 224 | 285 |
| 31 May 2024 | 262 | 287 |
| 28 Jun 2024 | 304 | 307 |
| 26 Jul 2024 | 312 | 317 |
| 23 Aug 2024 | 384 | 318 |
| 20 Sep 2024 | 366 | 329 |
| 18 Oct 2024 | 372 | 319 |
| 15 Nov 2024 | 394 | 299 |
| 13 Dec 2024 | 443 | 318 |
| 10 Jan 2025 | 425 | 296 |
| 7 Feb 2025 | 421 | 294 |
| 7 Mar 2025 | 388 | 278 |
| 4 Apr 2025 | 404 | 283 |
| 2 May 2025 | 400 | 299 |
| 30 May 2025 | 399 | 310 |
| 27 Jun 2025 | 384 | 321 |
| 25 Jul 2025 | 436 | 313 |
| 22 Aug 2025 | 445 | 313 |
| 19 Sep 2025 | 436 | 319 |
| 17 Oct 2025 | 464 | 321 |
| 14 Nov 2025 | 479 | 324 |
| 12 Dec 2025 | 456 | 323 |
| 9 Jan 2026 | 465 | 319 |
| 6 Feb 2026 | 474 | 319 |
| 6 Mar 2026 | 422 | 306 |
| 3 Apr 2026 | 412 | 285 |
| 1 May 2026 | 414 | 308 |
| 29 May 2026 | 439 | 308 |
| 26 Jun 2026 | 440 | 314 |
| 24 Jul 2026 | 453 | 312 |
| 21 Aug 2026 | 456 | 320 |
| 18 Sep 2026 | 454 | 311 |
| 16 Oct 2026 | 494 | 303 |
| 13 Nov 2026 | 488 | 323 |
Earnings, each company rebased to 100, the sector takes the median
Latest quarter April to June 2026: 165.5, from 3 companies
| Quarter | Median earnings index |
|---|---|
| Jul 2023 | 100.0 (2 companies) |
| Oct 2023 | 104.5 (2 companies) |
| Jan 2024 | 110.0 (2 companies) |
| Apr 2024 | 118.1 (2 companies) |
| Jul 2024 | 130.1 (2 companies) |
| Oct 2024 | 139.8 (2 companies) |
| Jan 2025 | 149.8 (2 companies) |
| Apr 2025 | 156.0 (2 companies) |
| Jul 2025 | 155.3 (3 companies) |
| Oct 2025 | 161.5 (3 companies) |
| Jan 2026 | 154.2 (3 companies) |
| Apr 2026 | 165.5 (3 companies) |
Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 3 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.
Is Diagnostic Services outperforming NIFTY 500?
Diagnostic Services has done worse than the NIFTY 500 by 15.8% over the last 52 weeks. Over 13 weeks the gap is a shortfall of 5.2%. Readings are as of 13 November 2026.
Relative-strength score for the industry: 11.9 as of 13 November 2026 (consolidation, falling).
What is the bottom line on Diagnostic Services?
Diagnostic Services has done worse than the NIFTY 500 by 15.8% over 52 weeks and by 5.2% over 13 weeks. 0 of 3 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months).
How does each Diagnostic Services stock score?
A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.
Dr Lal Pathlabs Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 62% evidence confidence.
- 1Dr Lal Pathlabs Ltdmixed, leaning good · 62% evidence62.2out of 100
How the score adds up
Growth & earnings 16.3/35 · Revenue 14.3% · PAT 5% · OPM change 1 pp · 95% evidenceCapital efficiency 23.4/25 · ROCE 28% (year to Mar 2026) · OPM 32% · 95% evidenceValuation 10.0/20 · P/E 57.5× · PEG — · 0% evidenceRelative strength 12.5/20 · RS sector — · RS bench 21.3% · 1Y — · 25% evidence · 6 of 6 weeks aheadExact sum: 16.3 + 23.4 + 10 + 12.5 = 62.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 2Chandan Healthcare LtdCHANDAN · quiet · mixed, leaning good · 61% evidence61.2out of 100
How the score adds up
Growth & earnings 21.7/35 · Revenue 20% · PAT 17.7% · OPM change 3.8 pp · 88% evidenceCapital efficiency 22.0/25 · ROCE 23.3% (year to Mar 2026) · OPM 24.2% · 100% evidenceValuation 10.0/20 · P/E 23.7× · PEG — · 0% evidenceRelative strength 7.5/20 · RS sector — · RS bench −10.1% · 1Y −27.2% · 25% evidence · 1 of 12 weeks aheadExact sum: 21.7 + 22 + 10 + 7.5 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 33B Blackbio DX Ltdmixed, leaning good · 65% evidence57.6out of 100
How the score adds up
Growth & earnings 18.6/35 · Revenue 33.3% · PAT 20.8% · OPM change −27.8 pp · 83% evidenceCapital efficiency 21.5/25 · ROCE 25.5% (year to Mar 2026) · OPM 25.4% · 95% evidenceValuation 10.0/20 · P/E 20.2× · PEG — · 35% evidenceRelative strength 7.5/20 · RS sector — · RS bench −5.7% · 1Y 1.8% · 25% evidence · 7 of 12 weeks aheadExact sum: 18.6 + 21.5 + 10 + 7.5 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
How this score is built, and what the marks mean
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
How have Diagnostic Services share prices moved?
3B Blackbio DX Ltd has the strongest one-year price move in Diagnostic Services at +1.8%. Dr Lal Pathlabs Ltd leads on relative strength against the NIFTY, at +21.3%. 1 of 3 companies we track is ahead of the index on that measure. Every line covers 314 weekly closes through 13 November 2026.
Price and relative strength
Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
RS vs sector: The same measure taken against Diagnostic Services itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
Biggest one-year moves
- 13B Blackbio DX Ltd₹1,120 cr+1.8%1 year
- 2Chandan Healthcare LtdCHANDAN · ₹586 cr−27.2%1 year
Strongest against NIFTY 500
- 1Dr Lal Pathlabs Ltd₹33,700 cr+21.3%vs NIFTY 500
- 23B Blackbio DX Ltd₹1,120 cr−5.7%vs NIFTY 500
- 3Chandan Healthcare LtdCHANDAN · ₹586 cr−10.1%vs NIFTY 500
Which Diagnostic Services companies have the most revenue, and which grow fastest?
Dr Lal Pathlabs Ltd has the highest Revenue among the 3 Diagnostic Services companies compared here, at ₹2,892 crore. Chandan Healthcare Ltd is next at ₹289 crore. 3B Blackbio DX Ltd has the highest Revenue growth at 33.3%, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Dr Lal Pathlabs Ltd is the largest at ₹2,892 crore, 899.7% ahead of Chandan Healthcare Ltd. 3B Blackbio DX Ltd's growth is 33.3% from a ₹128 crore base, with 15 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.
What this means: Dr Lal Pathlabs Ltd is the size to compare against; 3B Blackbio DX Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.
This conclusion weakens if: Dr Lal Pathlabs Ltd's growth falls below 3B Blackbio DX Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenue · company comparison
Revenue · largest
- 1Dr Lal Pathlabs Ltd₹2,890 cr
- 2Chandan Healthcare LtdCHANDAN₹289 cr
- 33B Blackbio DX Ltd₹128 cr
Revenue growth · fastest growers
- 13B Blackbio DX Ltd33%
- 2Chandan Healthcare LtdCHANDAN20%
- 3Dr Lal Pathlabs Ltd14%
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | ₹874 cr | 20% | Sep 2026 |
| Chandan Healthcare Ltd CHANDAN | ₹80.9 cr | 19% | Jun 2026 |
| 3B Blackbio DX Ltd | ₹33.5 cr | 51% | Jun 2026 |
Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.
What to watch
Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.
Which Diagnostic Services companies keep the most from each ₹100 of sales?
Dr Lal Pathlabs Ltd has the highest OPM among the 3 Diagnostic Services companies compared here, at 32%. 3B Blackbio DX Ltd is next at 25.4%. Chandan Healthcare Ltd has the highest Margin change at +3.8 percentage points, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Dr Lal Pathlabs Ltd leads opm at 32%; Chandan Healthcare Ltd leads margin change at +3.8 percentage points.
What this means: Dr Lal Pathlabs Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
Operating margin · company comparison
OPM, by reported quarter
- Dr Lal Pathlabs 32%
- 3B Blackbio DX 25%
- Chandan Healthcare 24%
| Quarter | Dr Lal Pathlabs | 3B Blackbio DX | Chandan Healthcare |
|---|---|---|---|
| Dec 2021 | 22% | 49% | — |
| Mar 2022 | 25% | 32% | — |
| Jun 2022 | 23% | 44% | — |
| Sep 2022 | 27% | 53% | — |
| Dec 2022 | 24% | 50% | — |
| Mar 2023 | 27% | 41% | — |
| Jun 2023 | 27% | 45% | — |
| Sep 2023 | 30% | 41% | — |
| Dec 2023 | 26% | 50% | — |
| Mar 2024 | 27% | 43% | 15% |
| Jun 2024 | 28% | 56% | 16% |
| Sep 2024 | 31% | 55% | 18% |
| Dec 2024 | 26% | 59% | 16% |
| Mar 2025 | 28% | 35% | 16% |
| Jun 2025 | 29% | 53% | 20% |
| Sep 2025 | 31% | 43% | 21% |
| Dec 2025 | 27% | 43% | 18% |
| Mar 2026 | 27% | 24% | 15% |
| Jun 2026 | 31% | 25% | 24% |
| Sep 2026 | 32% | — | — |
Margin change, by reported quarter
- Dr Lal Pathlabs +1.0 pp
- 3B Blackbio DX −27.8 pp
- Chandan Healthcare +3.8 pp
| Quarter | Dr Lal Pathlabs | 3B Blackbio DX | Chandan Healthcare |
|---|---|---|---|
| Dec 2021 | −8.7 pp | −10.0 pp | — |
| Mar 2022 | −3.4 pp | −12.9 pp | — |
| Jun 2022 | −7.8 pp | −11.4 pp | — |
| Sep 2022 | −1.5 pp | +13.6 pp | — |
| Dec 2022 | +2.0 pp | +1.5 pp | — |
| Mar 2023 | +2.1 pp | +8.8 pp | — |
| Jun 2023 | +3.6 pp | +0.8 pp | — |
| Sep 2023 | +3.1 pp | −12.4 pp | — |
| Dec 2023 | +2.0 pp | +0.2 pp | — |
| Mar 2024 | 0.0 pp | +2.0 pp | — |
| Jun 2024 | +1.0 pp | +11.3 pp | — |
| Sep 2024 | +1.0 pp | +14.9 pp | — |
| Dec 2024 | 0.0 pp | +9.2 pp | — |
| Mar 2025 | +1.0 pp | −7.8 pp | +1.4 pp |
| Jun 2025 | +1.0 pp | −3.1 pp | +4.6 pp |
| Sep 2025 | 0.0 pp | −12.0 pp | +2.9 pp |
| Dec 2025 | +1.0 pp | −16.2 pp | +1.9 pp |
| Mar 2026 | −1.0 pp | −11.2 pp | −1.2 pp |
| Jun 2026 | +2.0 pp | −27.8 pp | +3.8 pp |
| Sep 2026 | +1.0 pp | — | — |
3 of 3 companies report OPM, 3 of 3 margin change.
OPM · highest
- 1Dr Lal Pathlabs Ltd32%
- 23B Blackbio DX Ltd25%
- 3Chandan Healthcare LtdCHANDAN24%
Margin change · fastest expanders
- 1Chandan Healthcare LtdCHANDAN+3.8 pp
- 2Dr Lal Pathlabs Ltd+1.0 pp
- 33B Blackbio DX Ltd−27.8 pp
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | 32% | +1.0 pp | Sep 2026 |
| 3B Blackbio DX Ltd | 25% | −27.8 pp | Jun 2026 |
| Chandan Healthcare Ltd CHANDAN | 24% | +3.8 pp | Jun 2026 |
What to watch
Watch whether the next two comparable periods confirm the current margin change rather than reversing it.
Which Diagnostic Services companies earn the most profit?
Dr Lal Pathlabs Ltd has the highest Net profit among the 3 Diagnostic Services companies compared here, at ₹545 crore. 3B Blackbio DX Ltd is next at ₹58 crore. 3B Blackbio DX Ltd has the highest Profit growth at 20.8%, so level and change sit with different companies. Its Net profit series carries 16 reported observations across the 20-quarter window.
What the numbers say: Dr Lal Pathlabs Ltd earns the most, ₹545 crore of profit over the last 12 months, 839.7% above 3B Blackbio DX Ltd. 3B Blackbio DX Ltd shows 20.8% growth from a profit base of ₹58 crore. A fast rate from a small base matters less than a large profit that keeps coming.
What this means: Dr Lal Pathlabs Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profit · company comparison
Net profit · largest
- 1Dr Lal Pathlabs Ltd₹545 cr
- 23B Blackbio DX Ltd₹58 cr
- 3Chandan Healthcare LtdCHANDAN₹25.2 cr
Profit growth · fastest growers
- 13B Blackbio DX Ltd21%
- 2Chandan Healthcare LtdCHANDAN18%
- 3Dr Lal Pathlabs Ltd5.0%
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | ₹194 cr | 28% | Sep 2026 |
| 3B Blackbio DX Ltd | ₹9 cr | −29% | Jun 2026 |
| Chandan Healthcare Ltd CHANDAN | ₹7.9 cr | 28% | Jun 2026 |
What to watch
Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.
Which Diagnostic Services companies earn the best return on capital?
Dr Lal Pathlabs Ltd has the highest ROCE among the 3 Diagnostic Services companies compared here, at 28%. 3B Blackbio DX Ltd is next at 25.5%. 3B Blackbio DX Ltd has the highest ROCE change at −1 percentage points, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Dr Lal Pathlabs Ltd leads ROCE at 28%, 2.5 percentage points above 3B Blackbio DX Ltd. 3B Blackbio DX Ltd has the strongest latest improvement at −1 percentage points. A high return reported once may be one good year; a high return reported year after year shows a lasting business.
What this means: Dr Lal Pathlabs Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
Return on capital · company comparison
ROCE · highest
- 1Dr Lal Pathlabs Ltd28%
- 23B Blackbio DX Ltd26%
- 3Chandan Healthcare LtdCHANDAN23%
ROCE change · fastest improvers
- 13B Blackbio DX Ltd−1.0 pp
- 2Dr Lal Pathlabs Ltd−1.0 pp
- 3Chandan Healthcare LtdCHANDAN−4.5 pp
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Chandan Healthcare Ltd CHANDAN | 25% | −4.5 pp | Jun 2026 |
What to watch
Watch whether the next two comparable periods confirm the current roce change rather than reversing it.
How are Diagnostic Services stocks valued against growth and quality?
No company in this Diagnostic Services comparison reports a valuation figure this section can compare, so the PEG rank is empty. On P/E, 3B Blackbio DX Ltd is lowest at 20.2× at the latest share price, across 3 of 3 companies with a usable reading.
What the numbers say: There is not enough comparable evidence to name a reliable peg leader.
What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
Valuation · company comparison
P/E, by reported quarter
- 3B Blackbio DX 17.0×
- Dr Lal Pathlabs 58.3×
- Chandan Healthcare 30.8×
| Quarter | 3B Blackbio DX | Dr Lal Pathlabs | Chandan Healthcare |
|---|---|---|---|
| Dec 2021 | 8.0× | 78.8× | — |
| Mar 2022 | 9.3× | 59.9× | — |
| Jun 2022 | 8.8× | 49.0× | — |
| Sep 2022 | 13.0× | 77.4× | — |
| Dec 2022 | 15.6× | 76.0× | — |
| Mar 2023 | 13.4× | 62.6× | — |
| Jun 2023 | 12.7× | 78.9× | — |
| Sep 2023 | 20.9× | 79.9× | — |
| Dec 2023 | 24.5× | 71.4× | — |
| Mar 2024 | 22.3× | 57.3× | — |
| Jun 2024 | 29.4× | 64.9× | — |
| Sep 2024 | 30.9× | 71.7× | — |
| Dec 2024 | 39.7× | 61.4× | — |
| Mar 2025 | 28.9× | 49.7× | 27.2× |
| Jun 2025 | 25.8× | 48.1× | 22.9× |
| Sep 2025 | 23.9× | 52.2× | 25.6× |
| Dec 2025 | 24.4× | 44.0× | 29.2× |
| Mar 2026 | 17.4× | 40.5× | 22.0× |
| Jun 2026 | 17.0× | 53.9× | 30.8× |
| Sep 2026 | — | 58.3× | — |
0 of 3 companies report PEG, 3 of 3 P/E.
PEG · lowest PEG
Not enough comparable data.
P/E · lowest P/E
- 13B Blackbio DX Ltd20.2×
- 2Chandan Healthcare LtdCHANDAN23.7×
- 3Dr Lal Pathlabs Ltd57.5×
All-company data · latest reported quarter
| Company | P/E | Reported |
|---|---|---|
| 3B Blackbio DX Ltd | 17.0× | Jun 2026 |
| Dr Lal Pathlabs Ltd | 58.3× | Sep 2026 |
| Chandan Healthcare Ltd CHANDAN | 30.8× | Jun 2026 |
PEG is left out: no company here reports it on a comparable basis.
What to watch
Watch whether the next two comparable periods confirm the current p/e rather than reversing it.
Which stock lists do Diagnostic Services companies appear on?
Diagnostic Services companies show up on one of our India lists. The most are on the healthcare & hospital stocks list (1 company).
What can make this comparison misleading?
This Diagnostic Services comparison names 5 specific ways its own evidence can mislead, all listed below. All 3 companies here report on comparable dates, so no rank carries a stale marker. 1 of the 5 ranked sections has fewer than three usable current readings. A high growth rate can still come from a very small starting figure.
Keep these limits visible
- A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
- A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
- The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- Thin comparisons: Valuation have fewer than three usable current readings.
How was this comparison built?
This comparison is built from the reported filings of 3 Diagnostic Services companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 13 November 2026.
Every company's second-feed figures reconcile against the primary source on overlapping reported periods, so nothing here is unverified or withheld.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree, the figures are simply used. Where there is too little shared history to compare, the figures are still drawn, they are the only evidence there is, and marked unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
What else do people ask about Diagnostic Services stocks?
These 21 answers restate the Diagnostic Services comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 13 November 2026. Nothing here is estimated, and none of it is a recommendation.
Is the Diagnostic Services sector outperforming NIFTY 500?
Diagnostic Services has done worse than the NIFTY 500 by 15.8% over 52 weeks and by 5.2% over 13 weeks. 0 of 3 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months).
Which Diagnostic Services company is largest by revenue?
Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 3 of 3 comparable companies through Sep 2026.
Which Diagnostic Services company is growing fastest?
3B Blackbio DX Ltd has the fastest current revenue growth at 33.3%, across 3 of 3 comparable companies.
Which Diagnostic Services company has the strongest 4-Factor Sector Score?
Dr Lal Pathlabs Ltd ranks first at 62.2 out of 100, with 62% of the evidence available. The score ranks published data; it is not a recommendation.
How much history does this Diagnostic Services comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.
Is there a Nifty Diagnostic Services index?
The exchange runs Nifty indices for several broad sectors, such as Nifty Bank, Nifty IT and Nifty Pharma, but not for every smaller group on this site.
Whether or not an official Nifty index covers Diagnostic Services, this page builds its own equal-weight basket of 3 listed Diagnostic Services companies: one company, one vote, whatever its size, so no single large company dominates. Figures are as of Sep 2026.
Which are the best Diagnostic Services stocks in India?
Ranked by this page's four-factor score, Dr Lal Pathlabs Ltd comes first among 3 listed Diagnostic Services companies, followed by Chandan Healthcare Ltd. That is a ranking of published data (earnings, quality, valuation and share-price behaviour as of Sep 2026), not a recommendation.
How many Diagnostic Services stocks are listed in India?
This comparison covers 3 listed Diagnostic Services companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Sep 2026.
Which Diagnostic Services company is the biggest?
Dr Lal Pathlabs Ltd is the largest, with revenue of ₹2,892 crore over the last 12 months, ahead of Chandan Healthcare Ltd at ₹289 crore. That covers 3 of 3 companies with comparable reporting through Sep 2026.
Which Diagnostic Services company has the best profit margins?
Dr Lal Pathlabs Ltd has the highest operating margin at 32%, from 3 of 3 comparable companies. Chandan Healthcare Ltd shows the biggest recent improvement, at +3.8 percentage points. A high margin matters most when it is steady or rising, not when it is at a peak.
Which Diagnostic Services company makes the most profit?
Dr Lal Pathlabs Ltd earns the most, at ₹545 crore of net profit over the last 12 months, from 3 of 3 comparable companies. 3B Blackbio DX Ltd has the fastest profit growth at 20.8%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Diagnostic Services company earns the highest return on capital?
Dr Lal Pathlabs Ltd leads on return on capital employed at 28%, across 3 of 3 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.
Is the Diagnostic Services sector beating the market?
Diagnostic Services has done worse than the NIFTY 500 by 15.8% over the last 52 weeks and by 5.2% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 0 of the 3 companies we track are beating the market on their own.
Sector strength does not transfer evenly to every stock in it.
Which Diagnostic Services stock has the strongest price momentum?
Dr Lal Pathlabs Ltd has the strongest relative strength against the NIFTY 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.
Which Diagnostic Services company has the highest 4-Factor score?
Dr Lal Pathlabs Ltd scores 62.2 out of 100, with 62% of the evidence available, from 16.3 points on growth and earnings, 23.4 on capital efficiency, 10 on valuation and 12.5 on relative strength.
It ranks published data only; management quality, upcoming events and risks are not part of the score.
How many Diagnostic Services companies does this comparison cover, and over what period?
This comparison covers 3 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.
What is the total market cap of the Diagnostic Services sector?
The 3 Diagnostic Services companies on this page carry ₹35,400 crore of combined market value. Dr Lal Pathlabs Ltd is the largest at ₹33,690 crore, about 95% of the sector's total on its own. Market value moves with price, so this reading is dated 13 November 2026.
How is the Diagnostic Services sector performing?
0 of the 3 Diagnostic Services companies we track are doing better than the NIFTY 500 on relative strength (how a share price has done against the index over recent months). The sector itself is 15.8% behind NIFTY 500 over 52 weeks on an equal-weight index of its current members.
Readings are as of 13 November 2026.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.
Is this advice?
No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
Every India sector against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 13 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.